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1. Introduction  
1-(3-Chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) is a 
synthetic cathinone stimulant. It is a ring-substituted cathinone, which is structurally related 
to methcathinone (1) and 4-chloromethcathinone (4-CMC) (2).  
In Europe, 3-CMC is monitored by the EMCDDA as a new psychoactive substance (3) 
through the European Union Early Warning System (EWS) in accordance with Article 5a of 
Regulation (EC) No 1920/2006 (as amended) (4,5). 
3-CMC was formally notified as a new psychoactive substance (6,7) by the EMCDDA on 
behalf of Sweden on 14 October 2014. The notification was based on the identification of the 
substance in a police seizure of 0.72 grams of powder made on 22 September 2014 in 
Norrköping.  
Since the formal notification, information on 3-CMC has been exchanged between the 
EMCDDA and the European Union EWS Network (EMCDDA, Europol, Reitox national focal 
points, and the Commission); the EMA have been kept duly informed. 
The EMCDDA is currently monitoring 161 synthetic cathinones through the European Union 
Early Warning System (EU EWS). 
While the quantities of cathinone powders seized in Europe have been decreasing since 
they peaked in 2015 and 2016, at around 1 800 kg per year, and falling to 750 kg by 2019, 
during 2020 there was a significant increase, with approximately 3 300 kg of powders 
seized. It appears, that at least in part, this increase has been driven by 3-CMC which 
accounted for almost a quarter of the quantity of powders seized during 2020. In addition, 3-
methylmethcathinone (3-MMC), which is also currently the subject of an initial report 
following its emergence in Europe, accounted for a similar quantity. 
While information reported to the EMCDDA through the Early Warning System suggests that 
some synthetic cathinones seized in Europe have originated from China, recently, there 
have been an increasing number of reports of seizures that have originated from India, 
including those relating to seizures of 3-CMC and 3-MMC. In addition, there has also been a 
recent increase in the number of laboratories producing cathinones, including 3-CMC and 3-
MMC, seized in Europe. 
 
1 Listed in Schedule I of the 1971 United Nations Single Convention on Psychotropic Substances. 
2 Listed in Schedule II of the 1971 United Nations Single Convention on Psychotropic Substances. 
3 As defined in point 4 of Article 1 of Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum 
provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335, 11.11.2004, 
p. 8). 
4 Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European 
Monitoring Centre for Drugs and Drug Addiction (recast) (O J L 376, 27.12.2006, p.1-13). 
5 Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 2017 amending Regulation (EC) 
No 1920/2006 as regards information exchange on, and an early warning system and risk assessment procedure for, new 
psychoactive substances (O J L 305, 21.11.2017, p.1-7). 
6 EMCDDA. 2020. EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
substances. p. 15–6. http://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-
warning-system-on-new-psychoactive-substances_en 
7 EMCDDA. 2020. EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive 
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Article 5b of Regulation (EC) No 1920/2006 (as amended) requires that ‘Where the Centre, 
the Commission or a majority of the Member States considers that information shared on a 
new psychoactive substance collected pursuant to Article 5a in one or more Member States 
gives rise to concerns that the new psychoactive substance may pose health or social risks 
at Union level, the Centre shall draw up an initial report on the new psychoactive substance’.  
The initial report is submitted to the Commission and the Member States. The purpose of the 
initial report is to provide scientific evidence to the Commission to allow it to make an 
informed decision regarding whether or not there is a need to request a risk assessment on 
a new psychoactive substance as set out in Article 5c of Regulation (EC) No 1920/2006 (as 
amended). 
Based on the information reported by the Network, on 9 September 2021, the EMCDDA 
assessed the existing information (8,9) on 3-CMC, based on the following criteria:  
• reports of health problems; 
• reports of social problems; 
• reports of seized material; 
• pharmacological and toxicological properties and analogy with better-studied 
substances; and, 
• potential for further spread.  
The EMCDDA concluded that the assessment gave rise to concerns that 3-CMC may pose 
health or social risks at Union level, and, consequently, determined that an initial report 
should be produced. 
2. Information collection process 
In accordance with the requirements of Article 5b of the Regulation, on 13 September 2021, 
the EMCDDA launched a procedure for the collection of additional information on 3-CMC in 
order to support the production of the initial report.  
The EMCDDA collected information through: 
• a structured reporting form to the Reitox national focal points in the Member States, 
Turkey, and Norway (Article 5b(4)); 
• routine monitoring of open source information;  
• a search of open source information conducted specifically for the production of the 
initial report which included: scientific and medical literature, official reports, grey 
 
8 European Monitoring Centre for Drugs and Drug Addiction (2019), EMCDDA operating guidelines for the European Union 
Early Warning System on new psychoactive substances, Publications Office of the European Union, Luxembourg. 
http://www.emcdda.europa.eu/publications/guidelines/operating-guidelines-for-the-european-union-early-warning-system-on-
new-psychoactive-substances_en 
9 This included information reported to the EMCDDA through the Early Warning System, including case reports and aggregated 
datasets. 
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literature, internet drug discussion forums and related websites (hereafter, ‘user 
websites’), and online vendors. 
In addition, the EMCDDA also submitted requests to: 
• The World Health Organization (WHO) in order to determine if 3-CMC is under 
assessment or has been under assessment within the system established by the 
1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, and 
the 1971 Convention on Psychotropic Substances (‘United Nations system’). 
• The European Medicines Agency (EMA) in order to determine if 3-CMC is used as 
an active substance in a medicinal product for human or veterinary use at Union or 
national level (Article 5b(5)). Specifically, the EMA was asked if 3-CMC is an active 
substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that 
has obtained a marketing authorisation in accordance with Directive 2001/83/ 
EC of the European Parliament and of the Council (10), Directive 2001/82/EC 
of the European Parliament and of the Council (11) or Regulation (EC) No 
726/2004 of the European Parliament and of the Council (12);  
b. a medicinal product for human use or in a veterinary medicinal product that is 
the subject of an application for a marketing authorisation;  
c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority;  
d. an unauthorised medicinal product for human use in accordance with Article 5 
of Directive 2001/83/EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of 
Directive 2001/20/EC of the European Parliament and of the Council (13). 
• Europol in order to provide information on the involvement of criminal groups in the 
manufacture, distribution and distribution methods, and trafficking of 3-CMC, and in 
any use of 3-CMC (Article 5b(6)).  
 
10 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to 
medicinal products for human use (OJ L 311, 28.11.2001, p. 67). 
11 Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to 
veterinary medicinal products (OJ L 311, 28.11.2001, p. 1). 
12 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community 
procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a 
European Medicines Agency (OJ L 136, 30.4.2004, p. 1). 
13 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the 
conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34). 
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• The European Chemicals Agency (ECHA), the European Centre for Disease 
Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) in 
order to provide the information and data at their disposal on 3-CMC (Article 5b(7)). 
The information collection process was concluded on 8 October 2021. The EMCDDA 
received responses from all 27 Member States, Turkey, and Norway. In addition, the 
EMCDDA received responses from WHO, EMA, Europol, ECHA, ECDC, and EFSA. 
3. Methodological note 
3-CMC has been available on the drug market since 2014. Although 3-CMC is screened for 
in many forensic and toxicology laboratories in Europe, it cannot be excluded that some 
cases of 3-CMC are undetected or unreported, in particular in serious adverse events.  
3-CMC has two positional isomers, whose discrimination poses analytical challenges. Due to 
differences in reporting practices across Europe, the discrimination of 3-CMC from its 
positional isomers is done in many, but not all, forensic and toxicology laboratories. For the 
purposes of preparing this report, all detections where the positional isomer of 3-CMC has 
not been specified to the EMCDDA have been excluded from the data analysis of physical 
and biological samples. However, due to different reporting practices across Europe, it 
remains possible that some detections reported as 3-CMC but that are actually a different 
positional isomer, have been included. 
For serious adverse events (SAEs), cases reported to the EMCDDA where the positional 
isomer has not been specifically denoted have been included in the data analysis. However, 
these cases are classified in the text as cases of ‘suspected exposure’ and not as 
analytically confirmed cases. Certainty of exposure according to the Drug Exposure 
Classification System (DECS) follows the same classification employed for SAEs. 
Complementary data sources have been used in the preparation of the Initial Report: 
- For the period comprised between 1 January 2014 and 31 December 2020, annual 
aggregated seizure data which is systematically reported to the EMCDDA has been 
used.  
- For the period comprised between 1 January and 30 September 2021, event-based 
data reported spontaneously to the EMCDDA, as well as data reported through 
targeted requests for information (a structured reporting form sent to the Reitox 
national focal points and responses to ad hoc information requests) have been used. 
The bulk of this data, which is partial for the year 2021 and subject to change, has 
been collected in two weeks and is not comparable to aggregated seizure data. 
- Open source information identified through routine monitoring has also been used 
throughout the report, when confirmed by Reitox national focal points.  
Information on seizures reported by police and customs agencies is analysed separately. In 
some cases, the seizure was either reported by the laboratory that analysed the sample, 
without specifying whether the seizure was made by police or customs, the identity of the 
reporting authority was either not specified by the reporting country or not clear from the 
reports submitted to the EMCDDA. These cases are referred to as ‘Other seizures’. 
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4. Information required by Article 5b(2) of the Regulation 
The order and titles of subsections 4.1 to 4.9, below, are as they appear in Article 5b(2) of 
Regulation (EC) No 1920/2006 (as amended); sections 4.1 to 4.4 are cross-referenced with 
the headings of Article 5b(2a) to Article 5b(2d) of the Regulation. 
4.1 Nature, number and scale of incidents showing health and social problems in 
which the new psychoactive substance may potentially be involved, and the patterns 
of use of the new psychoactive substance (Article 5b(2a)) 
4.1.1 Information from seizures, collected samples and biological samples 
The available evidence suggests that 3-CMC has been present on the European drugs 
market since at least September 2014. The substance has been detected across a total of 
23 Member States, and Norway. These detections relate to 9 607 seizures, 67 collected 
samples and 213 biological samples. 
Most reports related to the first identification of 3-CMC in a country occurred between 2014 
and 2016 (n=16; 67%), around the first identification in Europe. 
Information from seizures  
In total, 9 607 seizures, amounting to 2.7 tonnes of material (in all physical forms) were 
reported by 23 countries. Of these, 1.1 tonnes were reported in the period of 2014 to 2020. 
The remaining 1.6 tonnes were reported in 2021. 
The large majority of the cases reported (9 375; 98%) were seizures of powders, amounting 
to 2.7 tonnes (Figure 1). To a much lesser extent, seizures of tablets and capsules (196 
cases), other or unknown physical forms (21), herbal material (7), liquids (7), blotters (1), 
were also reported. For this reason, the following analysis is focused on seizures of 
powders. 
A total of 9 375 seizures of powders were reported. The majority of cases comprise police 
seizures (6 702 cases; 71%). There were 533 cases reported by customs (6%) and 2 140 
other seizures (23%) for which the seizing authority is either not reported or not known.  
The majority of cases were reported by Poland (7 663 cases; 82%). The country reporting 
the largest quantities of seized powders was the Netherlands (2.1 tonnes; 78%). Of these, 
697 kg were seized in 2020, and 1.4 tonnes in 2021, by Dutch customs. 
A summary of the information reported is provided below. 
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Figure 1. Quantity of 3-chloromethcathinone (3-CMC) powder seized in kg — Europe, 1 
January 2012– 30 September 2021 
 
Customs seizures 
Since 2014, customs authorities have reported 533 seizures of 3-CMC amounting to 2.2 
tonnes of powders. Of these, 165 seizures (1.4 tonnes; 65%) occurred in 2021. While most 
seizures were reported by Sweden (199 cases; 37%), the largest quantities of powders were 
seized in the Netherlands (2.1 tonnes; 94% of customs seizures).  
Customs seizures were typically larger in quantity than those reported by police and provide 
some evidence of attempts to import large amounts of 3-CMC powders to Europe. 
The largest single seizure was also reported by Dutch customs and occurred in 2021. The 
seizure comprised of 400 kg of 3-CMC powders, also containing iso-3-CMC, which may 
have been leftover impurity of synthesis. An additional 4 seizures, weighing a total of 1 tonne 
of 3-CMC powders were also reported by Dutch customs in 2021.  
For the majority of customs seizures, the origin of the consignment was not reported (520 
cases; 1.5 tonnes). For the 13 cases where the origin of the consignment is known, the 
largest quantity of powders originated in India (6 seizures pure powder amounting to 695 kg, 
seized in the Netherlands, in 2020). In addition, 2 seizures were reported in 2015 which 
originated in China and amounted to 5.9 kg. Whenever European countries were mentioned 
as the country of origin (n=5), the consignments were typically small (less than 5 grams). 
Belgium and the Netherlands were the only countries of origin mentioned in those cases. 
The purity of 3-CMC detected was rarely reported. In the seizures that originated in India, 3-
CMC consisted of pure white powders. Sometimes, they were reported as ‘crystals’ or 
‘rocks’. When reported, labels referred to ‘‘‘3-CMC’’’ or ‘‘‘Clophedrone’’’.  
For the very few cases were other substances were reported, the powders typically 
contained other stimulants such as other cathinones (including 3-MMC) and, amphetamine 
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was detected in 3-CMC powders. Adulterants and diluents reported included caffeine, 
benzocaine, menthol and mannitol. 
Police seizures 
Since 2014, police authorities have reported 6 702 seizures of powders containing 3-CMC, 
amounting to 322 kg (Figure 2).  
Poland, Germany and Sweden reported 99% of the powders seized (6624 seizures 
amounting to 318 kg). Poland reported 94% of all Police seizures (6329 cases) and half of 
the quantity of powders seized by police (160 kg); German Police reported 28 seizures (102 
kg); and Swedish police reported 267 seizures (57 kg powders) all of which occurred in 
2021. The remaining countries reported considerably smaller amounts. 
Figure 2. Quantity of 3-chloromethcathinone (3-CMC) powder seized by police in kg — 
Europe, 1 January 2012– 30 September 2021 
 
The largest single seizure of 3-CMC by police occurred in 2020 in Germany, in Bavaria. The 
seizure consisted of 80 kg of powders contained in barrels labelled ‘‘‘Clophedron’’’. No other 
substances were detected.  
In reports of police seizures, quantification of the purity of the powders is typically not 
provided. In the 12 cases where quantitative information on purity was provided (reported by 
Germany) powders ranged from 79.5% to 98.1% purity. The purest powders were reported 
as the hydrochloride salt of 3-CMC and the less pure were reported as the base form. 
Other substances detected in police seizures (not quantified) included other cathinones 
(including 4-CMC, 191 cases) and to a lesser extent illicit substances (such as 
amphetamine, MDMA, and cocaine) as well as ketamine. Adulterants and diluents reported 
included caffeine, benzocaine, lidocaine, paracetamol, caffeine, alanine and citric acid. 
Powders were often described from as crystals, ranging from 'colourless crystals' to white, or 
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Other seizures  
In 2 140 cases, the reporting authority was not reported or unknown. These cases amounted 
to 157 kg of powders. Of these, 116 kg (74%) were seized in 2021 by Poland, in 624 cases. 
In these cases, other cathinones (including 3-MMC and 4-CMC), and illicit drugs (MDMA 
and amphetamine) were also detected. 
Information from collected samples  
A total of 67 collected samples were reported to the EMCDDA, between 2015 and 2021, by 
7 Member States: Austria (6), Czechia (1), France (2), Poland (55), Portugal (1), Slovenia 
(1), and Spain (1). Of these, 66 samples were in powder form.  
Samples were collected by drug-checking services (10 cases) or in the context of pilot drug 
checking projects (4). A total of 48 collected samples were also reported by the Polish 
Central Customs and Tax Laboratory in 2019.  
3-CMC was the only substance detected in 50 cases. In 17 cases, it was detected in 
combination with other cathinones: 4-CMC (6 cases); 4-CMC and 4-CEC (4); 4-CMC, 4-FPD 
and 4-CEC (2), 4-CEC (1), methcathinone (1), N-methyl-N,N-dimethylcathinone (1), and 3-
MMC (1). In the latter case, the sample was reported to contain 38.7% of the hydrochloride 
salt of 3-CMC. In one case it was detected in combination with caffeine (1).  
3-CMC was sold as other cathinones in 3 cases – as 3-MMC in 1 case, and as 4-MMC in 2 
cases, where it was detected in combination with 4-CMC. In view of this, it is possible that 
some users might consume the substance inadvertently when purchasing other cathinones. 
Information on where the samples were purchased, packaging and pricing is mostly 
unreported. When reported, the substance was bought online (3 cases).  
The scientific literature has limited information regarding collected samples of 3-CMC. There 
is only one recorded instance where other substances were missold as 3-CMC – a sample 
bought as 3-CMC which contained 4-CMC (Grifell et al. 2017).  
Information from biological samples 
A total of 213 detections where 3-CMC was analytically confirmed in biological samples 
were reported by 4 Member States: Sweden (182), Hungary (18), Poland (12) and Spain (1). 
Serious adverse events with confirmed exposure to 3-CMC from biological samples — 1 
acute poisoning reported by Spain and 10 deaths reported by Poland (7) and Sweden (3) — 
are discussed in Section 4.1.2. 
In addition to these, 202 detections of 3-CMC in biological samples were reported by 
Sweden (179), Hungary (18) and Poland (5). The biological samples were reported between 
2015 and 2021 as follows: 2015 (18 samples), 2016 (1), 2017 (48), 2018 (13), 2019 (17), 
2020 (36), 2021 (69). Detections included: 
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- 4 samples associated with deaths, reported by Sweden (14); 
- 2 samples associated with non-fatal poisonings, reported by Hungary (15); 
- 27 samples associated with petty drug offences, reported by Sweden; 
- 21 cases of persons suspected of driving under the influence of drugs, reported by 
Sweden (16), Poland (3) and Hungary (2); 
- 15 samples analysed for criminal justice purposes, reported by Hungary (14) and 
Poland (1); 
- 15 samples associated with abuse cases, reported by Sweden;  
- 6 samples analysed for drug treatment purposes, reported by Sweden; and 
- 112 samples reported as aggregated data associated with forensic case work 
(details not specified), reported by Sweden (111) and Poland (1). 
4.1.2 Health problems 
Acute poisonings 
One acute non-fatal poisoning with confirmed exposure to 3-CMC was reported by Spain 
and was related to chemsex (16). Other substances were identified in biological samples, 
including 3-MMC, GHB/GBL, cocaine, sildenafil, and methamphetamine.  
In addition, France and Sweden reported cases of serious adverse events without analytical 
confirmation from biological samples. These include one case of drug dependence reported 
by France and 47 acute poisonings with suspected exposure to 3-CMC reported to the 
Swedish Poisons Information Centre between 2015 and 2021: 2015 (7 cases), 2016 (4), 
2017 (8), 2018 (8), 2019 (6), 2020 (7), and 2021 (7). These cases are not discussed further 
in this report. 
Deaths 
A total of 10 deaths with confirmed exposure to 3-CMC were reported by Poland (7) and 
Sweden (3). The cases occurred between November 2019 and June 2021 (one case in 
2019; three cases in 2020; six cases in 2021). Of the deaths, eight were male and two were 
female. Where reported, the males were aged between 17 and 47 (mean: 30.5; median: 
39.5). 
In six of the cases, other substances were identified, including central nervous system 
depressants (such as alcohol, opioids, synthetic cannabinoids and benzodiazepines) and 
central nervous system stimulants (such as amphetamine and other synthetic cathinones). 
 
14  These samples were reported in aggregated datasets, and there is no correspondence between the number of samples and 
number of serious adverse events (SAEs), as more than one sample may have been taken from the same patient. SAEs 
reported in aggregated datasets may or may not overlap with event-based SAEs discussed in Section 4.1.2. 
15  These samples were reported in aggregated datasets, and there is no correspondence between the number of samples and 
number of serious adverse events (SAEs), as more than one sample may have been taken from the same patient. SAEs 
reported in aggregated datasets may or may not overlap with event-based SAEs discussed in Section 4.1.2. 
16  Chemsex is a term used to describe an intentional sex under the influence of psychoactive drugs, mostly among men who 
have sex with men. 
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Of note is that in two of the cases where other substances where identified, the only 
additional finding was alcohol. In at least three of the cases, the individuals were found 
dead. A cause of death was reported in nine cases. In five cases, 3-CMC was the cause of 
death or contributed to the death; in the remaining cases, the reported causes of death were 
multi-organ trauma as a result of a traffic accident (in two cases), intoxication with 
oxycodone and benzodiazepines (in one case), and gunshot wound to the chest (in one 
case).  
ECDC reported that currently they do not have any information on 3-CMC. 
4.1.3 Social problems 
While there is limited data on the social risks related to the use of 3-CMC, it is possible that 
they share some similarities with those associated with other synthetic cathinones like 4-
MMC. Depending on the user group, these might include changes in the social and 
economic conditions of the individual, impact their family structure and employment 
situation, as well as confer increased vulnerability (Brookman et al. 2016). 
4.1.4 Patterns of use 
The limited information suggests that 3-CMC is sold and sought after as a stimulant drug in 
its own right, but it may also be mis-sold as other drugs. Similar to other cathinones, such as 
4-CMC, it is likely that 3-CMC is typically administered by insufflation (snorting), orally, and 
in some cases by intravenous injection. It is expected that the substance is used by existing 
stimulant users, such as those who use cocaine, amphetamines, ecstasy, and other 
cathinones, who either add it to their existing repertoire or use it as a replacement 
substance. This likely includes recreational use, and, in some cases high risk use, such as 
injecting. Although specific information is lacking, similar to other cathinones, it is likely that 
3-CMC is used in private spaces (such as homes and domestic parties) as well as 
recreational settings (such as nightclubs, bars/pubs, music festivals). 
4.2 Chemical and physical description of the new psychoactive substance and the 
methods and precursors used for its manufacture or extraction (Article 5b2(b)) 
4.2.1 Chemical description and names 
3-CMC is a synthetic derivative of the naturally occurring substance cathinone, which is 
internationally controlled (17), and one of the psychoactive principles in khat (Catha edulis 
Forsk). 3-CMC was described in the scientific literature in the months prior to its first 
detection on the drug market in Europe in September 2014 (Blough et al., 2014). 
As with many other synthetic cathinone derivatives monitored by EMCDDA through the EU 
Early Warning System, 3-CMC is an N-alkylated and ring-substituted cathinone.  
 
 
17 Listed in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. 
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The common name 3-CMC is derived from 3-chloromethcathinone (18). 3-CMC is the 3-
chloro derivative of methcathinone (19) and a positional isomer (20) of 4-CMC (4-
chloromethcathinone) (21), which are both internationally controlled. 3-CMC is structurally 
related to 3-MMC (3-methylmethcathinone) (22), differing on the substituent present at the 3-
position of the phenyl ring. Higher and lower homologues of 3-CMC monitored by the 
EMCDDA are: 3-CEC (3-chloroethcathinone) (23) and 3-chlorocathinone (24), respectively. 
 
The molecular structure, molecular formula and molecular mass of 3-CMC are provided in 
Figure 3. 
Figure 3. Molecular structure, molecular formula, and molecular mass of 3-CMC. 
Information on 4-CMC, methcathinone and 3-MMC is provided for comparison 
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Systematic (IUPAC) name: 
1-(3-Chlorophenyl)-2-(methylamino)propan-1-one  
(RS)-1-(3-chlorophenyl)-2-(methylamino)propan-1-one 
Other chemical names: 
1-(3-Chlorophenyl)-2-(methylamino)-1-propanone  
 
18 The origin for the abbreviated common name is indicated by underlining the relevant letters in the common name. 
19  2-(methylamino)-1-phenyl-propan-1-one; listed in Schedule I of the 1971 United Nations Single Convention on Psychotropic 
Substances. 
20  Positional isomers (also known as regioisomers) have the same molecular formula and molecular weight, differing only in 
the position of a functional group or substituent. 
21  1-(4-Chlorophenyl)-2-(methylamino)propan-1-one; formally notified by the EMCDDA in August 2014; and listed in Schedule 
II of the 1971 United Nations Single Convention on Psychotropic Substances. 
22  2-(Methylamino)-1-(3-methylphenyl)propan-1-one; formally notified by the EMCDDA in September 2012. 
23  1-(3-Chlorophenyl)-2-(ethylamino)propan-1-one; formally notified by the EMCDDA in March 2016. 
24  2-Amino-1-(3-chlorophenyl)propan-1-one; formally notified by the EMCDDA in November 2020. 
 













Chemical Abstracts Service (CAS) registry numbers: 
 1049677-59-9 (base) 
 1607439-32-6 (hydrochloride salt) 
 2291021-63-9 (R-isomer) 
 2107425-89-6 (S-isomer) 
IUPAC International Chemical Identifier Key (InCHI Key): 
VOEFELLSAAJCHJ-UHFFFAOYSA-N (base) 
QXEPSICDXPPHTO-UHFFFAOYSA-N (hydrochloride salt) 
VOEFELLSAAJCHJ-SSDOTTSWSA-N (R–isomer) 
VOEFELLSAAJCHJ-ZETCQYMHSA-N (S–iomer) 
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Simplified Molecular-Input Line-Entry System (SMILES): 
 O=C(c1cc(Cl)ccc1)C(C)NC (base) 
 Cl.CNC(C)C(=O)c1cccc(Cl)c1 (hydrochloride salt) 
CN[C@H](C)C(=O)c1cccc(Cl)c1 (R-isomer) 
CN[C@@H](C)C(=O)c1cccc(Cl)c1 (S-isomer) 
4.2.2 Physical description 
There is limited information available on the solubility, lipophilicity, melting and boiling points 
or other physico-chemical properties of 3-CMC. 
The hydrochloride salt of 3-CMC has been described in the literature as a grey solid 
(Blough, 2014), a white solid (Shalabi et al., 2017) and a white powder (SWGDRUG, 2017; 
RESPONSE, 2015), with melting points of 181 – 183 °C (Blough et al., 2014) and 193 °C 
(Shalabi et al., 2017) reported. Shalabi et al., noted that due to the 10 °C discrepancy in the 
melting point they obtained relative to the literature, the hydrochloride salt was submitted for 
microanalysis (Shalabi et al., 2017). 
Due to its similarity to 4-CMC, 3-CMC is expected to be soluble in organic solvents such as 
dimethyl formamide (DMF) and dimethyl sulfoxide (DMSO) or solvents such as ethanol 
(ECDD, 2019; Cayman Chemical, 2014). 
To date, seizures and collected samples containing 3-CMC reported to the EMCDDA have 
been mostly in powder form and, to a lesser extent, in tablet, capsule and liquid form. 3-
CMC has also been identified in herbal material and found in trace amounts in a syringe.  
3-CMC has been identified in combination with other cathinones, including but not limited to: 
2-MMC (25), 3-MMC, 3-CEC (26), 4-CEC (27), 4-CMC, 4-MEC (28), α-PVT (29), eutylone (30), 
mexedrone (31) and N-ethylhexedrone (32). 3-CMC has also been identified in combination 
with a variety of other categories of substances including synthetic cannabinoids such as 4F-
MDMB-BINACA (4F-MDMB-BUTINACA) (33) and internationally controlled substances such 
as cocaine, MDMA, amphetamine and metamphetamine. 
In at least some of the detections, the hydrochloride salt form of 3-CMC was identified. 










33 Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 
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4.2.3 Methods and chemical precursors used for the manufacture or extraction 
Limited information is available about the chemical precursors or manufacturing methods 
used to make the 3-CMC which has been identified within Europe. General methods for the 
synthesis of cathinones, including 3-CMC are described below. 
General methods for the synthesis of cathinones, including 3-CMC 
Cathinones may be prepared using several synthetic approaches. For ring-substituted 
cathinones, such as 3-CMC and 3-MMC, the simplest approach involves a 2-step 
bromination-amination procedure which is a relatively straightforward process, using 
equipment and knowledge similar to those required for the synthesis of other synthetic drugs 
such as MDMA and amphetamine (EMCDDA, 2011). 
The first step of the process consists in the α-bromination of a suitable arylketone 
(commonly called a ‘‘propiophenone’’’), to produce an α-bromoketone under acidic or basic 
conditions. The bromine for this step can be commercially obtained as a liquid or prepared 
from a bromide salt (e.g. KBr), an acid (e.g. H2SO4), and an oxidizer (e.g. H2O2). Importantly, 
bromine is toxic by inhalation, accelerates the burning of combustible material, is very 
corrosive to tissue and to metals and dangerous for the environment. 
After the preparation of the α-bromoketone, the product is reacted with an amine (for ring 
substituted cathinones the amine is typically methylamine hydrochloride and triethylamine in 
an acidic scavenger). This step promotes the nucleophilic substitution of the bromine to 
obtain a free cathinone base (IV) (EMCDDA, 2011; Wrzesień, 2018). Due to the instability of 
the free base, the product is converted into suitable salts (hydrochlorides or hydrobromides) 
which are then recrystallised (EMCDDA, 2011; Wrzesień, 2018). Unless steps are taken to 
resolve the reaction products, the synthesis produces racemic mixtures. In case the starting 
arylketone precursor is unavailable or controlled, it can be easily prepared by a standard 
Friedler-Crafts reaction, mixing the appropriate aryl derivative with propionyl chloride in the 
presence of aluminium chloride (Wrzesień, 2018). A standard Grignard reaction with the 
corresponding ring-substituted benzene is also possible.  
The preparation of cathinones using this method is an ‘industrially efficient’ process. 
Intermediate can be produced on a large scale, sub-divided into lots and each lot reacted 
with a different amine to produce a number of different cathinones (Collins, 2016). 
Numerous alternative synthetic methods exist. One of the most relevant ones is the so-
called ‘‘‘permanganate process’’’, which involves the direct oxidation of a suitable ephedrine 
analogue with a strong oxidant (potassium permanganate (VII) or potassium dichromate in 
diluted sulfuric acid) to yield the desired cathinone. If is obtained in a specific enantiomeric 
form, the synthesis is stereoselective and the resulting cathinone will be enantiopure, which 
may be of interest one of the forms is more active than the other. Although this method can 
yield stereoselective products, it presents important disadvantages in that manganese 
impurities can contaminate the end products, unless careful and thorough purification steps 
are taken. Cathinone products contaminated with manganese may cause serious poisoning 
in consumers (EMCDDA, 2011). 
A general synthesis scheme for methcathinone derivatives, including 3-CMC, has been 
described by Blough et al., (Blough et al., 2019). Two specific methods for the synthesis of 
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the hydrochloride salt of 3-CMC have been described in the literature by Blough et al., 
(compound 9) and by Shalabi et al., (compound 6) (Blough et al., 2014; Shalabi, 2017).  
For 3-CMC, Blough et al., treated 3-chloropropiophenone with bromine to yield 2-bromo-1-
(3’-chlorophenyl)-1-oxopropane, which was then reacted with N-benzylmethylamine to 
produce 2-(N-benzyl-N-methylamino)-1-(3’-chlorophenyl)-1-oxopropane. This was then 
mixed with 1-chloroethyl chloroformate in dichloroethane to afford 3-CMC hydrochloride as a 
grey solid (Blough et al., 2014). Shalabi et al., reacted 2-bromo-1-(3-chlorophenyl)propan-1-
one with methylamine, in the presence of ethanol to yield 3-CMC hydrochloride as a white 
solid (Shalabi et al., 2017).  
Designer Precursors 
Other than standard organic synthesis methods using known precursors, cathinones can be 
prepared using so-called ‘‘designer precursors’’. These are ‘‘purpose-made, close chemical 
relatives of controlled precursors and can easily be converted into a controlled precursor and 
usually have no legitimate use.’’ (CND, 2020). They can be, for example, stable chemical 
intermediates, masked derivatives of controlled precursors, or masked derivatives of 
controlled drugs. (CND, 2020). Amine compounds, including cathinones, are especially 
suited for the latter approach, in that ‘‘masking’’ or ‘‘protecting’’ groups (such as acetyl 
protecting groups, ‘‘Boc’’ groups, CBZ groups and/or ‘‘Tosyl’’ groups for example) can be 
easily introduced into the molecule (making it a different chemical entity) and then easily 
cleaved off, often in quantitative yields to produce the controlled amine of choice.  
Illicit production of 3-CMC  
Information on the synthetic pathways used to produce the 3-CMC seized in Europe can 
come from impurity profiling of seized/collected samples, from seizures of cathinone 
precursors and from law enforcement intelligence collected in seizures of illicit cathinone 
production sites. 
Limited information exists on the synthetic impurities present in 3-CMC samples. 
Approximately 400 kg of 3-CMC powders, also containing iso-3-CMC, were seized by Dutch 
Customs in 2021. Isocathinones such as iso-3-CMC, can be by-products of cathinone 
synthesis (Westphal et al.; 2012; Wrzesień, 2018), occurring when the amino moiety and the 
keto group change place in the molecule. Their occurrence is attributed to the first synthetic 
pathway (bromination/amination), which, as already explained above, is the most 
‘‘industrially efficient’’ method to fabricate these compounds. 
Seizures of precursors reported to the European Commission do not contain information on 
specific chemicals needed for the synthesis of 3-CMC. Most of the reports consisted of 
precursors for 4-MMC and 4-CMC, which can nonetheless be taken as indicative of the 
processes used for their positional isomers. The majority of cathinone precursors seized 
between 2015 and 2019 were chemicals needed for amination step in the 
bromination/amination. This suggests that cathinone labs in Europe may be using the 
pathway in question but and that they may be focused on the final stages of cathinones 
production (‘finishing labs’). 
Law enforcement information reported to the EMCDDA by law enforcement authorities 
indicates that at least 55 cathinone illicit laboratories have been dismantled in Europe since 
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2011. Close to 50% of the laboratories were seized between 2019 and 2021, suggesting that 
there has been an increase in the interest in producing cathinones in Europe.  
Of the 55 laboratories seized, 3 sites were involved in the production of 3-CMC: one seized 
in Slovakia in 2017, and 2 seized in Poland in 2020. 
4.2.4 Detection and analysis 
Methods documented in the literature for the identification of 3-CMC in physical samples and 
biological samples are referenced in Table 1.  
Table 1. Methods documented in the literature for the identification of 3-CMC in physical 
samples and biological samples 
Physical samples 
Method References 
Gas chromatography–mass spectrometry (GC-MS)  Blough et al., 2014 
SWGDRUG, 2017 
Cayman Chemical, 2015 
RESPONSE, 2015 
Fourier transform infrared spectroscopy (FTIR) SWGDRUG, 2017 
RESPONSE, 2015 
Piorunska-Sedlak et al., 2020 
High-performance liquid chromatography-ultraviolet 
(HPLC-UV) 
Hägele et al., 2020 
Kadkhodaei et al., 2018 
Kadkhodaei et al., 2020 
Raman spectroscopy Kranenburg et al., 2021 
Chiral capillary electrophoresis (CEC) Hägele et al., 2019 
1H nuclear magnetic resonance spectroscopy (NMR) Blough et al., 2014 
SWGDRUG, 2017 
RESPONSE, 2015 
13C NMR RESPONSE 2015 
Biological samples 
Method References 
HPLC and supercritical fluid chromatography tandem 
mass spectrometry (SFC-MS/MS) 
Lajtai et al., 2020 
Gas chromatography tandem mass spectrometry (GC-
MS/MS) 
Woźniak et al., 2020 
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Quantification of 3-CMC in physical samples can be carried out according to the general 
procedure described by the UNODC (UNODC, 2020). Due to its structural similarity to 4-
CMC, quantification of 3-CMC in blood samples could be carried out according to the 
procedure described by Wiergowski et al., using UPLC–MS/MS (Wiergowski et al., 2017).  
Discrimination of 3-CMC from its positional isomers 
3-CMC has two positional isomers, 2-CMC (34) and 4-CMC, differing only in the position of 
the chlorine atom on the phenyl ring. Reference standards of the hydrochloride salt of 3-
CMC (Cayman Chemical, 2015), 2-CMC (Cayman Chemical, 2017), and 4-CMC (Cayman 
Chemical, 2014) are commercially available. Reference standards are also commercially 
available for the base form and the S-isomer of 3-CMC (Aurora Fine Chemicals, 2021a; 
Aurora Fine Chemicals, 2021b). 
Positional and structural isomers have the same molecular formula and molecular mass, 
therefore the discrimination of these isomers of 3-CMC poses analytical challenges, as 
techniques solely relying on mass will not allow an unequivocal identification. The positional 
isomers of 3-CMC, 2-CMC and 4-CMC, can be discriminated for in many, but not all, 
forensic and toxicology laboratories in Europe. The discrimination of positional isomers can 
be achieved through the use of analytical reference standards, access to reference spectra 
for the positional isomers and/or analytical methods in addition to GC-MS, such as FTIR or 
NMR. The discrimination of these isomers is described in further detail below. 
Analysis by GC-MS will result in very similar mass spectrometry fragmentation patterns. 
Hägele et al. highlighted that discrimination by GC-MS is particularly challenging when using 
common achiral columns (Hägele et al., 2019; Hägele et al., 2020). The ability to distinguish 
between these isomers requires the use of analytical reference standards, access to 
reference spectra for both substances, and/or additional analytical methods, such as FTIR or 
NMR. 
Hägele et al. demonstrated that positional isomers can be discriminated by use of capillary 
electrochromatography (CEC), providing the example of the discrimination of three different 
fluorinated methcathinone derivatives, 2-FMC (35), 3-FMC (36) and 4-FMC (37), with 
carboxymethyl-β-CD as the chiral selector (Hägele et al., 2019). Kadkhodaei et al., also 
demonstrated that using an isocratic HPLC method with a specific CSP could discriminate 
between the three positional isomers of mephedrone (2-MMC, 3-MMC and 4-MMC) 
(Kadkhodaei et al., 2020). It could be expected that the discrimination of 2-CMC, 3-CMC and 
4-CMC is possible using these methods.  
Piorunska-Sedlak et al., demonstrated that 3-CMC could be discriminated from 4-CMC using 
ATR-IR, as the spectra are sufficiently different (Piorunska-Sedlak et al., 2020). 2-CMC was 
not included in the analysis as it was not identified in the 45 samples studied (Piorunska-
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A validated GC–MS/MS method for the determination of NPS in blood samples from forensic 
cases has been described by Woźniak et al. (Woźniak et al., 2020). The authors explained 
that while 3-CMC and 4-CMC had close retention times and shared the same multiple 
reaction monitoring (MRM) transitions, the identification of these compounds was facilitated 
by the use of internal standards and by calculation of their relative retention times. It was 
highlighted by the authors that the method is limited to screening, with quantification only 
possible when only one of these analytes is present in a sample (Woźniak et al., 2020). 
3-CMC is also a structural isomer of iso-3-CMC (38). Iso-3-CMC is not currently monitored by 
the EMCDDA but other iso-cathinones monitored by the EMCDDA are: 3-fluoro-
isomethcathinone (3-FiMC) (39) iso-pentedrone (40) and iso-ethcathinone (41). Iso-3-CMC has 
been recently identified, alongside 3-CMC, in two significant seizures reported by Customs 
in the Netherlands, amounting to 400 kilograms of powder, that occurred in the first half of 
2021. The presence of iso-3-CMC in these seizures could be as a result of dimerisation due 
to the reaction of the alpha-haloketone and the amine. The detection of iso-cathinones in 
seized samples has been discussed in the literature (McDermott et al. 2011). Based on the 
authors hypotheses in their study of iso-mephedrone and iso-ethcathinone, the detection of 
iso-3-CMC could be due to the starting material for 3-CMC having been contaminated with 
the starting material for the iso-3-CMC, or from the use of liquid amine rather than amine in 
solution during synthesis, or possibly as a result of rearrangement of 3-CMC directly to iso-
3-CMC through an imino-amine intermediate (McDermott et al. 2011). The authors 
suggested that, based on their findings, the use of liquid amine was the likely factor in the 
presence of the iso-cathinone compounds identified in seized samples and as these were 
not commonly identified in samples this ‘could be used to compare batches of material and 
suggest a common origin’ (McDermott et al. 2011). 
 
Differentiation of enantiomers  
Cathinones such as 3-CMC contain a stereogenic centre thus allowing for the existence of a 
pair of enantiomers, (R)- and (S)-3-CMC. There is no information on the enantiomeric 
composition of the samples of 3-CMC detected within the European Union, which in part 
may reflect the fact that stereochemical analysis is not routinely undertaken in forensic 
laboratories.  
Differentiation of enantiomers is possible using the following techniques: chiral 
chromatography, vibrational circular dichroism (VCD) spectroscopy and/or electronic circular 
dichroism (ECD) spectroscopy. 
Hägele et al., reported the use of an isocratic HPLC method with a specific chiral stationary 
phase (CSP), developed for the enantioresolution of synthetic chiral drugs, to successfully 
separate enantiomers of a range of new psychoactive substances, including 3-CMC (Hägele 
et al., 2020). Kadkhodaei et al., also demonstrated the separation of a range of NPS 
enantiomers using an isocratic HPLC method with a specific CSP (Kadkhodaei et al., 2018). 
The authors highlighted that in general ‘for a successful chiral separation, the position and 
 
38 1-(3-Chlorophenyl)-1-(methylamino)propan-2-one 
39 1-(3-Fluorophenyl)-1-(methylamino)propan-2-one; formally notified by the EMCDDA in February 2012 
40 1-(Methylamino)-1-phenylpentan-2-one; formally notified by the EMCDDA in September 2011 
41 1-(Ethylamino)-1-phenylpropan-2-one; formally notified by the EMCDDA in June 2010 
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the atomic mass of halogen substituents play a crucial role’, with substitution in the ortho 
position considered to produce less satisfactory results than in the para position. This was 
demonstrated by the successful chiral separation of 3-CMC and 4-CMC compared with 2-
CMC (Kadkhodaei et al., 2018).  
4.3 Pharmacological and toxicological description of the new psychoactive substance 
(Article 5b2(c)) 
3-CMC is a ring-substituted synthetic cathinone. Similar to closely related cathinones such 
as 4-chloromethcathinone (clephedrone, 4-CMC), 3-CMC has been shown to interact with 
the monoamine transporter system in a number of in vitro studies, which suggest that 3-
CMC acts as a psychostimulant. For example, 3-CMC was reported to act as a monoamine 
(dopamine, noradrenaline and serotonin) transporter substrate that induces release in rat 
brain synaptosomes (Kohut et al. 2013, Blough et al. 2014, Shalabi et al. 2017, Blough et al. 
2019, Walther et al. 2019). This mechanistic principle is also found in other closely related 
ring-substituted synthetic cathinones such as 4-MMC, methcathinone, and 4-CMC (Walther 
et al. 2019). 3-CMC was also observed to produce sustained and selective decreases in 
cocaine self-administration in rhesus monkeys and produced fewer side effects than 
methcathinone (Kohut et al. 2013). 3-CMC was also 3–8 fold less potent than cocaine or 
methcathinone in eliciting cocaine-like discriminative stimulus effects in rhesus monkeys 
(Kohut et al. 2013). Consistent with a locomotor stimulant profile, 3-CMC was observed to 
increase spontaneous horizontal locomotor activity in mice in a dose-dependent manner 
(Wojcieszak et al. 2020). Taken together, these results suggest that 3-CMC is likely to act as 
a stimulant in humans and might also show abuse liability. Acute effects of synthetic 
cathinones include stimulant effects such elevated mood, euphoria, and increased energy 
but undesired effects reflecting a sympathomimetic toxidrome are known to include 
hyperthermia, tachycardia, hypertension, and psychosis (Baumann et al. 2018).  
The acute effects of 3-CMC are likely to share some similarities with other substituted 
cathinones such as 4-CMC. These might include general stimulation, euphoria, sociability, 
increased heart rate and elevated blood pressure (Abdulrahim and Bowden-Jones, 2015; 
Soares et al., 2021). Synthetic cathinones also have an abuse liability and dependence 
potential (Bajaj et al., 2010; Batisse, et al., 2014; Dolengevich-Segal et al., 2016). 
There is limited information on the acute toxicity of 3-CMC. Based on the available 
information, the clinical features of poisoning are likely to be similar to those observed with 
other synthetic cathinones. Adverse effects from overdosing 3-CMC might include 
neurological (e.g. hallucination, seizures, agitation, anxiety, psychosis, reduced 
consciousness), cardiovascular (e.g. tachycardia, hypertension, chest pain, cardiac arrest) 
and respiratory (e.g. bradypnea, dyspnoea) clinical features (Abdulrahim and Bowden-
Jones, 2015; Soares et al., 2021). 
Similar to other stimulant cathinones, the use of 3-CMC with other central nervous system 
stimulants, including cocaine, amphetamine, methamphetamine or MDMA, is likely to 
produce synergistic effects which can increase the risk of an acute intoxication. 
While there is limited information for 3-CMC, the chronic health risks might share some 
similarities to those seen with other synthetic cathinones such as 4-CMC. This may include 
dependence. 
 
23 of 35 
ECHA reported to the EMCDDA that according to the Classification and Labelling (C&L) 
Inventory, 3-CMC hydrochloride salt is classified as an eye irritant category 2. EFSA 
reported to the EMCDDA that they do not currently have any information on 3-CMC.  
4.4 Involvement of criminal groups in the manufacture or distribution of the new 
psychoactive substance (Article 5b2(d)) 
Europol received replies from 13 Member States (Austria, Bulgaria, Croatia, Cyprus, 
Denmark, Finland, France, Germany, Greece, Luxembourg, Poland, Slovakia and Slovenia) 
and Norway. 
Replies were also received from Iceland (42), the United Kingdom (UK) (43) and the United 
States Drug Enforcement Administration (DEA) (44). 
Involvement of criminal groups in the manufacture or distribution of 3-CMC 
Poland reported the seizure of two clandestine laboratories producing 3-CMC, in the last 
year. They reported that they do not currently have accurate data on the involvement of 
criminal groups in the manufacture, distribution and distribution methods, and trafficking of 3-
CMC.  
Slovakia reported a significant decrease in the activities of foreign criminal groups, dealing 
with the production of 3-CMC, according to information from the police. This decrease is 
considered to be a result of Covid-19 restrictions.  
No other information was received on the involvement of criminal groups in the manufacture 
or distribution of 3-CMC. 
Information on seizures of 3-CMC 
In general, seizures of 3-CMC reported to Europol occurred between 2015 and 2021. 
- Austria reported a slight increase in cases involving 3-CMC in recent years. 3-CMC 
has been seized as a white powder, and as a brown liquid which was also found to 
contain cocaine and/or 4-MMC.  
 
42 Iceland reported that no information was available on 3-CMC. 
43 The UK reported that according to records from the Border Force on the INCB IONICS system, there were ten incidents 
involving 3-CMC so far in 2021. The UK was the destination country for seven of the ten shipments, while Poland (2) and 
Ukraine (1) were the other destinations. The Netherlands was the origin country for all ten shipments. In the case of the 
shipment destined for the Ukraine, it appears to have transited through the UK, where it was seized. In total, they reported that 
there have been 82 incidents worldwide associated with 3-CMC, which have been recorded in the system since March 2015.  
44 The DEA reported that information on seizures of 3-CMC have been provided by the DEA laboratory information 
management system (LIMS) since it became the official record in October 2014. Information on other detections from forensic 
laboratories other than the DEA system has also been provided by the Diversion Control Division’s NFLIS database. The DEA 
reported that it is not aware of any domestic synthesis of 3-CMC and the substance is often purchased via the surface or dark 
web and then shipped to the US. They noted that some of the seizures appeared to be labelled as research chemicals, which 
they believe could have been purchased from chemical supply companies. A total of three detections of 3-CMC were identified 
in the DEA LIMS in 2016, in crystalline, rock and powder form, ranging in quantity from 0.96 to 54.463 grams. In one case, the 
hydrochloride salt form of 3-CMC was identified and, in the other two cases, 3-CMC was identified with alpha-PVP and an 
unidentified substance. A total of 16 detections of 3-CMC were registered in the Diversion Control Division’s NFLIS database, 
recorded between 2015 and 2019.  
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- Denmark reported that most seizures of 3-CMC, approximately ten, were of small 
quantities associated with personal consumption, seized in postal packages 
originating from countries within the EU. 
- Finland reported minor and infrequent seizures of 3-CMC, by police and customs, 
also reported to the EMCDDA. 
- France reported that 3-CMC has been identified in detections since 2014 and 
according to information available to French police and OFDT (45) is available to 
purchase online, at a reported price of 14 to 18 euro per gram. Information from 
analysis by OFDT indicates that 3-CMC has been identified in products sold online 
as 3-MMC. They also reported that while some seizures of 3-MMC have been 
reported by French law enforcement services, no 3-CMC seizures have been 
reported.  
- Germany reported that all information has been sent to the EMCDDA by the DBDD 
(46). 
- Greece reported generally on 3-CMC, in the context of more specific information 
provided on 3-MMC.Norway reported that 3-CMC was seized for the first time in 
Norway in 2015, with tens of seizures reported between 2015 and 2017, followed by 
a decrease in seizures from 2017. From 2020, an increase in seizures was observed 
with more than 15 seizures of 3-CMC in crystal form reported; the largest individual 
seizure during this timeframe was 2.5 kilograms. 
- Slovakia reported two seizures of 3-CMC made by the police during four raids in 
2019 (148.2 grams; and 0.76 grams also containing 3-CEC (3-chloroethcatinone). 
- Slovenia reported that a total of 30 grams of 3-CMC was identified in seizures in 
2019, from individuals who mostly purchased the substance online. 
Austria, Bulgaria, Denmark and Greece reported information on the national control 
measures applied to 3-CMC and/or 4-CMC. Croatia, Cyprus and Luxembourg reported that 
no information is available.  
4.5 Information on the human and veterinary medical use of the new psychoactive 
substance, including as an active substance in a medicinal product for human use or 
in a veterinary medicinal product 
Based on the reported information from the EMA (47), it appears that 3-CMC is not an active 
substance in: 
a. a medicinal product for human use or in a veterinary medicinal product that has 
obtained a marketing authorisation in accordance with Directive 2001/83/ EC of the 
European Parliament and of the Council, Directive 2001/82/EC of the European 
 
45 The French Observatory for Drugs and Drug Addiction (OFDT)  
46 The German Monitoring Centre for Drugs and Drug Addiction (DBDD) 
47 26 Member States, as well as Norway and Iceland provided a response to the EMA’s request regarding human and/or 
veterinary medicinal products. 
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Parliament and of the Council or Regulation (EC) No 726/2004 of the European 
Parliament and of the Council;  
b. a medicinal product for human use or in a veterinary medicinal product that is the 
subject of an application for a marketing authorisation;  
c. a medicinal product for human use or in a veterinary medicinal product whose 
marketing authorisation has been suspended by the competent authority. 
In addition, it appears that 3-CMC is not an active substance in the following, although the 
information, especially in relation to use in extemporaneously prepared products, is unknown 
in some cases: 
d. an unauthorised medicinal product for human use in accordance with Article 5 of 
Directive 2001/83/ EC or in a veterinary medicinal product prepared 
extemporaneously by a person authorised to do so under national law in 
accordance with point (c) of Article 10(1) of Directive 2001/82/EC;  
e. an investigational medicinal product as defined in point (d) of Article 2 of Directive 
2001/20/EC of the European Parliament and of the Council. 
4.6 Information on the commercial and industrial use of the new psychoactive 
substance, the extent of such use, as well as its use for scientific research and 
development purposes 
3-CMC is available as an analytical reference material in clinical and forensic case work and 
is used scientific research. There is currently no information that suggests 3-CMC is used for 
other legitimate purposes.  
ECHA reported that there are no registrations or classification and labelling (C&L) 
notifications for 3-CMC in the C&L Inventory database (48).  
ECHA reported a C&L notification for the hydrochloride salt of 3-CMC that classifies the 
substance as an eye irritant category 2, and labels it with hazard statement H319 (‘causes 
serious eye irritation’) (ECHA). The identity of C&L notifiers is not published on the ECHA 
dissemination website, due to the sensitivity of this information. 
EFSA holds no information on 3-CMC and has not assessed this substance in any context.  
4.7 Information on whether the new psychoactive substance is subject to any 
restrictive measures in the Member States 
Six Member States (Bulgaria, Greece, Luxembourg, the Netherlands, Romania, and Spain) 
reported that 3-CMC is not subject to restrictive measures at national level.  
 
48 ECHA’s C&L Inventory database contains classification and labelling information on notified and registered substances 
received from manufacturers and importers. It also includes the list of harmonised classifications. The information included in 
the preparation of this report is public 
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When reporting whether 3-CMC is subjected to restrictive measures, 11 Member States 
(Austria, Belgium, Croatia, Denmark, France, Germany, Hungary, Ireland, Latvia, Lithuania, 
and Malta) and Turkey mentioned that this substance is covered by the generic definition of 
cathinones. 
Drug control legislation 
Thirteen Member States (Croatia, Czechia, Denmark, Estonia, France, Italy, Ireland, Latvia, 
Poland, Portugal, Slovenia, Slovakia, and Sweden), Turkey and Norway reported that 3-
CMC is controlled under drug control legislation. 
• Croatia reported that 3-CMC is controlled by generic definition since 2014; 
• Czechia reported that 3-CMC is controlled since 2017; 
• Denmark reported that 3-CMC is covered by generic cathinone classification since 
2012; 
• Estonia reported that 3-CMC is controlled under the Act on Narcotic Drugs and 
Psychotropic Substances and Precursors thereof, List VI, since 2016; 
• France reported that 3-CMC is controlled by a generic approach since 2012; 
• Ireland reported that 3-CMC is covered by the generic cathinone definition under 
Statutory Instrument 551/2011, in force since November 2011;  
• Italy reported that 3-CMC was included in the list of new psychoactive substances in 
the update of 6 August 2021 of the decree of the President of the Republic n. 309; 
• Latvia reported that 3-CMC is covered by generic definition in the law On the 
Procedures for the Coming into Force and Application of the Criminal Law;  
• Poland reported that 3-CMC is controlled by a regulation of the Minister of Health 
since 2018;  
• Portugal reported that 3-CMC is included in Law No. 25/2021 of 11 May which 
amends for the twentieth-seventh time the Decree-Law No. 15/93 of 22th January, 
as of 11 May 2021. 
• Slovenia reported that 3-CMC is controlled by the Regulation on the Classification of 
Illicit Drugs since 2016; 
• Slovakia reported that 3-CMC is controlled by Act No. 139/1998 Coll. on Narcotics 
and Psychotropic Substances and Preparations since 1 January 2020; 
• Sweden reported that 3-CMC was regulated as goods dangerous to health as of 18 
August 2015 and was re-scheduled as a narcotic drug in 2019; 
• Turkey reported that 3-CMC was controlled by generic legislation in the context of 
Law on Control of Drugs numbered 2313, since 2016; 
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• Norway reported that 3-CMC is classified as a narcotic in Norway and is listed in 
Narcotics legislation. Private import by mail is not permitted and companies need 
licenses to import, export, or manufacture 3-CMC. 3-CMC is also classified as a 
‘forbidden’ narcotic, meaning even stricter regulations regarding licenses for 
import/export/manufacture. 
New psychoactive substance legislation 
Seven Member States (Austria, Belgium, Cyprus, Germany, Finland, Hungary, and Malta) 
reported that 3-CMC is controlled under new psychoactive substance legislation.  
• Austria reported that 3-CMC is covered by generic definition by the Austrian Act on 
New Psychoactive Substances of 2012;  
• Belgium reported that 3-CMC is covered by generic definition; 
• Cyprus reported that 3-CMC is controlled since 2011; 
• Germany reported that 3-CMC is covered by the New Psychoactive Substances Act 
since 2016; 
• Finland reported that 3-CMC is banned by a government decree on psychoactive 
substances since 2015; 
• Hungary reported that 3-CMC is covered by the definition of cathinones in Annex I of 
Decree no. 55/2014 of the Ministry of Human Capacities, Substances since 2012. 
• Malta reported that 3-CMC is not explicitly mentioned in their laws. Police prosecutes 
the substance, as it is considered a derivative of cathinone and a new psychoactive 
substance. 
Medicines legislation 
Lithuania reported that 3-CMC is controlled under medicines legislation (included in the 
group of cathinone derivatives) since 10 March 2015.  
Other information 
3-CMC is controlled in China since October 2015.  
4.8 Information on whether the new psychoactive substance is currently or has been 
under assessment within the system established by the 1961 Single Convention on 
Narcotic Drugs, as amended by the 1972 Protocol, and the 1971 Convention on 
Psychotropic Substances 
The World Health Organization is the specialised United Nations agency designated for the 
evaluation of the medical, scientific, and public health aspects of psychoactive substances 
under the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic 
Substances, 1971. 
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On 17 September 2021, the World Health Organization informed the EMCDDA that 3-CMC 
is not currently under assessment nor has it been under assessment by the United Nations 
system.  
4.9 Other relevant information 
Austria 
In Austria, the drug checking service CheckIt reported two samples containing 3-CMC and 
4-CMC in January 2020. Both samples were submitted as mephedrone (CheckIt, 2021). 
Switzerland  
In Switzerland, the drug checking service SaferParty reported 8 samples containing 3-CMC 
between May 2019 and October 2021. In all cases 3-CMC was sold as other substance: 3-
MMC (in 4 cases) (49), MDMA (2), methamphetamine (1), and mephedrone (1). Three 
samples contained other substances such as MDMA, 4-CEC, 3-MMC, 4-MMC, and 
ketamine (SaferParty, 2021).  
!  
 
49 In one of these cases, the sample was sold as ‘5-MMC’, which would be equivalent to 3-MMC. 
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5. Analysis and assessment 
1-(3-Chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) is a 
synthetic cathinone with stimulant effects that is monitored as a new psychoactive substance 
by the EMCDDA in accordance with Regulation (EC) No 1920/2006. The substance is an N-
alkylated and ring-substituted cathinone and contains a chiral centre so two enantiomers 
may exist: (R)-3-CMC and (S)-3-CMC. It is a derivative of cathinone, the naturally occurring 
stimulant and main psychoactive substance in the khat plant Catha edulis. 3-CMC is also 
closely related to and shares similar stimulant effects with methcathinone (ephedrone) and 
4-chloromethcathinone (4-CMC; clephedrone). Cathinone, methcathinone, and 4-CMC are 
controlled under the 1971 United Nations Convention on Psychotropic Substances because 
of the public health and social risks that they pose. 
3-CMC was first identified in Europe in September 2014 based on a police seizure made in 
Sweden. Despite appearing on the drug market at around the same time as 4-CMC, until 
2020, the detection of 3-CMC in law enforcement seizures remained relatively low in 
comparison to 4-CMC. However, during 2020 and 2021 there has been a large increase in 
seizures of 3-CMC. Although the reasons for this are unclear, it does coincide with the 
recent control of 4-CMC under the United Nations system in 2020. At least in part, it appears 
that 3-CMC is being used as a ‘legal’ replacement to 4-CMC. 
The limited information suggests that 3-CMC is sold and sought after as a stimulant drug in 
its own right, but it may also be mis-sold as other drugs. Similar to other cathinones, such as 
4-CMC, it is likely that 3-CMC is typically administered by insufflation (snorting), orally, and 
in some cases by intravenous injection. It is expected that the substance is used by existing 
stimulant users, such as those who use cocaine, amphetamines, ecstasy, and other 
cathinones, who either add it to their existing repertoire or use it as a replacement 
substance. This likely includes recreational use, and, in some cases high risk use, such as 
injecting. Although specific information is lacking, similar to other cathinones, it is likely that 
3-CMC is used in private spaces (such as homes and domestic parties) as well as 
recreational settings (such as nightclubs, bars/pubs, music festivals). 
Since 2014, 3-CMC has been identified in 23 Member States and Norway. In total, 
approximately 2 720 kg of 3-CMC powder has been seized, including at least 2240 kg by 
customs and 320 kg by police. However, of this, approximately 2 500 kg (92%) was seized 
between 2020 and 2021. During 2021, 3-CMC continues to be imported, distributed, and 
used in parts of Europe; this includes the seizure of a total of 1 400 kg of powder at the 
external EU border. 
The available information suggests that 3-CMC is currently imported into Europe in bulk 
quantities mainly from India, with approximately 700 kg of pure powders that originated from 
the country seized in 2020. It is then processed, packaged, and then distributed in wholesale 
and retail amounts in Europe either online or by street dealers. In addition, three illicit 
laboratories producing 3-CMC have been seized in Europe, with the two most recent 
laboratories seized in 2020. 
Of particular note, is that while the quantities of cathinone powders seized in Europe have 
been decreasing since they peaked in 2015 and 2016, at around 1 800 kg per year, and 
falling to 750 kg by 2019, during 2020 there was a significant increase, with approximately   
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3 300 kg of powders seized. It appears, that at least in part, this increase has been driven by 
3-CMC which accounted for just over a quarter of the quantity of powders seized during 
2020. In addition, 3-methylmethcathinone (3-MMC), which is also currently the subject of an 
initial report following its re-emergence in Europe, accounted for a similar quantity. 
One acute non-fatal poisoning with confirmed exposure to 3-CMC has been reported by one 
Member State: Spain. Other substances were identified. 
A total of 10 deaths with confirmed exposure to 3-CMC have been reported by two Member 
States: Poland and Sweden. In six cases, other substances were identified. The cases 
occurred between November 2019 and June 2021; three of the deaths occurred in 2020 and 
six in 2021. In five cases, 3-CMC was the cause of death or contributed to the death. 
Currently, there is limited information on the involvement of criminal groups in the 
manufacture, trafficking, and distribution of 3-CMC within Europe. However, based on 
information reported to the EMCDDA, there is evidence of criminal acts, such as trafficking, 
illicit production, and supply offences, involving 3-CMC. 
The effect of the ongoing COVID-19 pandemic on the manufacture, trafficking, distribution 
and use of 3-CMC is currently unknown. However, seizures of more than of 2 170 kg of bulk 
powders by customs agencies during the pandemic suggest that 3-CMC continues to be 
imported and distributed in Europe. It is possible that, in case of a reduced availability of 
controlled stimulants (such as 4-CMC and MDMA) in Europe, criminal groups, as well as 
drug users, may use a range of replacement substances, including 3-CMC. 
Based on the available information, it appears that 3-CMC is not an active substance in a 
medicinal product for human use or in a veterinary medicinal product in Europe. However, 
the use of 3-CMC as an active substance in medicinal products prepared extemporaneously 
or in investigational medicinal products cannot be excluded in some Member States due to a 
lack of information. Aside from limited use as an analytical reference standard and in 
scientific research, there is currently no information that suggests that 3-CMC is used for 
other legitimate purposes. 
3-CMC is subject to restrictive measures in 21 Member States, Turkey, and Norway. 3-CMC 
is controlled in China. It is unknown if 3-CMC is controlled in India, from where bulk 
quantities of pure powder have originated and recently been seized by customs agencies in 
Europe.  
3-CMC has not been subject to assessment nor is it currently under assessment by the 
United Nations system. 
The EMCDDA will continue to intensively monitor 3-CMC to ensure that new information is 
provided to the Member States, Europol, the Commission and the EMA through the 
European Union Early Warning System in a timely manner, to strengthen situational 
awareness as well as to continue to inform preparedness and response measures at both 
national and EU levels to protect public health.  
Based on the analysis of the available information, especially the signals suggesting the 
recent emergence of 3-CMC, the EMCDDA considers that there are indications that 3-CMC 
may pose health or social risks at Union level. We conclude that the potential health and 
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social risks posed by the use, manufacture, distribution and involvement of criminal groups 
could be thoroughly assessed through a risk assessment procedure in accordance with 
Article 5c of Regulation (EC) No 1920/2006. 
!  
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